NexCure launched with a $19 million Series A financing round, aiming to deliver CAR-T and other clinically intensive treatments in community-based outpatient settings.
The financing round was led by RA Capital Management, with participation from Cencora Ventures and Oncology Ventures.
The company was founded by Raven, RA Capital’s health care incubator, to address capacity constraints and access challenges for lifesaving therapies. According to NexCure , out of 6,100 hospitals in the U.S., only ~200 – just 3% – administer CAR-T therapy.
The company’s proprietary platform standardizes protocols, automates care coordination, and reduces operational variability, enabling advanced therapies to be delivered beyond a small number of academic centers. This financing will support NexCure as it builds out the operating system for clinically intensive therapy delivery, integrating clinical decision support, remote monitoring, and operational intelligence.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!